Knockdown of growth factor receptor bound protein 7 suppresses angiogenesis by inhibiting the secretion of vascular endothelial growth factor A in ovarian cancer cells

References

• Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–296.
   PubMed Web of Science ®Google Scholar
• Luvero D, Plotti F, Aloisia A, et al. Ovarian cancer relapse: from the latest scientific evidence to the best practice. Crit Rev Oncol Hematol. 2019;140:28–38.
   PubMed Web of Science ®Google Scholar
• Lee JM, Minasian L, Kohn EC. New strategies in ovarian cancer treatment. Cancer. 2019;125(Suppl 24):4623–4629.
   PubMedGoogle Scholar
• Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28:viii1–viii7.
   PubMed Web of Science ®Google Scholar
• García García Y, Marín Alcalá M, Martínez Vila C. Anti-angiogenic therapy for ovarian cancer. EJC Suppl. 2020;15:77–86.
   PubMedGoogle Scholar
• Guan LY, Lu Y. New developments in molecular targeted therapy of ovarian cancer. Discov Med. 2018;26:219–229.
   PubMed Web of Science ®Google Scholar
• Viallard C, Larrivee B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20:409–426.
   PubMed Web of Science ®Google Scholar
• Lim D, Do Y, Kwon BS, et al. Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer. BMB Rep. 2020;53:291–298.
   PubMed Web of Science ®Google Scholar
• Ueda M, Terai Y, Kanda K, et al. Tumor angiogenesis and molecular target therapy in ovarian carcinomas. Hum Cell. 2005;18:1–16.
   PubMedGoogle Scholar
• Gómez-Raposo C, Mendiola M, Barriuso J, et al. Angiogenesis and ovarian cancer. Clin Transl Oncol. 2009;11(9):564–571.
   PubMed Web of Science ®Google Scholar
• Grunewald T, Ledermann JA. Targeted therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:139–152.
   PubMed Web of Science ®Google Scholar
• Chelariu-Raicu A, Horn A, Jonglertham P. Anti-angiogenesis therapy in ovarian cancer: which patient is it most likely to benefit? Oncology (Williston Park). 2019;33(1):33.
   PubMedGoogle Scholar
• Pero SC, Daly RJ, Krag DN. Grb7-based molecular therapeutics in cancer. Expert Rev Mol Med. 2003;5(14):1–11.
   PubMedGoogle Scholar
• Zeng M, Yang Z, Hu X, et al. Grb7 gene amplification and protein expression by FISH and IHC in ovarian cancer. Int J Clin Exp Pathol. 2015;8:11296–11304.
   PubMedGoogle Scholar
• Zheng Y, Pei Y, Yang L, et al. GRB7 promotes proliferation and tumorigenesis of bladder cancer via Phospho-AKT pathway. Int J Biol Sci. 2020;16:3221–3230.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chan DW, Liu VW. Differential functions of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in ovarian carcinogenesis. Clin Cancer Res. 2010;16:2529–2539.
   PubMed Web of Science ®Google Scholar
• Chen K, Liu MX, Mak CS, et al. Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness by targeting GRB7 and MAPK/ERK pathways. Theranostics. 2018;8:423–436.
   PubMed Web of Science ®Google Scholar
• Chan DW, Hui WW, Cai PC, et al. Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells. PLoS One. 2012;7:e52578.
   PubMedGoogle Scholar
• Lertkiatmongkol P, Liao D, Mei H. Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Curr Opin Hematol. 2016;23(3):253–259.
   PubMed Web of Science ®Google Scholar
• Schmidt LH, Biesterfeld S, Kümmel A, et al. Tissue microarrays are reliable tools for the clinicopathological characterization of lung cancer tissue. Anticancer Res. 2009;29:201–209.
   PubMed Web of Science ®Google Scholar
• Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467:596–599.
   PubMed Web of Science ®Google Scholar
• Guo H, Xia B. Collapsin response mediator protein 4 isoforms (CRMP4a and CRMP4b) have opposite effects on cell proliferation, migration, and invasion in gastric cancer. BMC Cancer. 2016;16(1):565.
   PubMedGoogle Scholar
• Xiao J, Chen B, Wang Q. Paeonin extracted from potatoes protects gastric epithelial cells from H(2)O(2)-induced oxidative damage in vitro by PI3K/Akt-mediated Nrf2 signaling pathway. Sci Rep. 2018;8:10865.
   PubMed Web of Science ®Google Scholar
• Lin J, Cao S, Wang Y, et al. Wang Q and Zheng L. Long non-coding RNA UBE2CP3 enhances HCC cell secretion of VEGFA and promotes angiogenesis by activating ERK1/2/HIF-1α/VEGFA signalling in hepatocellular carcinoma. J Exp Clin Cancer Res. 2018;37(1):113.
   PubMedGoogle Scholar
• Shi M, Chen X, Li H. δ-tocotrienol suppresses the migration and angiogenesis of trophoblasts in preeclampsia and promotes their apoptosis via miR-429/ ZEB1 axis. Bioengineered. 2021;12(1):1861–1873.
   PubMed Web of Science ®Google Scholar
• Chazotte B. Labeling nuclear DNA using DAPI. Cold Spring Harb Protoc. 2011;2011(1). pdb.prot5556. DOI:10.1101/pdb.prot5556.
   Google Scholar
• Dai F, Luo F, Zhou R, et al. Calponin 3 is associated with poor prognosis and regulates proliferation and metastasis in osteosarcoma. Aging (Albany NY). 2020;12(14):14037–14049.
   PubMedGoogle Scholar
• Cheng GY, Jiang Q, Deng AP, et al. CD31 induces inflammatory response by promoting hepatic inflammatory response and cell apoptosis. Eur Rev Med Pharmacol Sci. 2018;22:7543–7550.
   PubMed Web of Science ®Google Scholar
• Nefedova NA, Kharlova OA, Danilova NV. Markers of angiogenesis in tumor growth. Arkh Patol. 2016;78:55–63.
   PubMedGoogle Scholar
• Figueiredo CC, Pereira NB, Pereira LX, et al. Double immunofluorescence labeling for CD31 and CD105 as a marker for polyether polyurethane-induced angiogenesis in mice. Histol Histopathol. 2019;34:257–264.
   PubMed Web of Science ®Google Scholar
• Xu L, Xu C, Lin X. Interference with lysophosphatidic acid receptor 5 ameliorates oxidized low-density lipoprotein-induced human umbilical vein endothelial cell injury by inactivating NOD-like receptor family, pyrin domain containing 3 inflammasome signaling. Bioengineered. 2021;12(1):8089–8099.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Mendelson DS, Kato G. Tumor angiogenesis and novel antiangiogenic strategies. Int J Cancer. 2010;126(8):1777–1787.
   PubMed Web of Science ®Google Scholar
• Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114–127.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist. 2015;20(6):660–673.
   PubMed Web of Science ®Google Scholar
• Lugano R, Ramachandran M, Dimberg A. Ramachandran M and Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77(9):1745–1770.
   PubMed Web of Science ®Google Scholar
• Melincovici CS, Boşca AB, Şuşman S, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59:455–467.
   PubMed Web of Science ®Google Scholar
• Namiecińska M, Marciniak K, Nowak JZ. Marciniak K and Nowak JZ. [VEGF as an angiogenic, neurotrophic, and neuroprotective factor]. Postepy Hig Med Dosw (Online). 2005;59:573–583.
   PubMedGoogle Scholar
• Hellström M, Phng LK, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007;445:776–780.
   PubMed Web of Science ®Google Scholar
• Jakobsson L, Bentley K, Gerhardt H. VEGFRs and Notch: a dynamic collaboration in vascular patterning. Biochem Soc Trans. 2009;37(6):1233–1236.
   PubMedGoogle Scholar
• Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene. 2016;35(8):939–951.
   PubMed Web of Science ®Google Scholar